Clinical Trial Update: Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase II trial is evaluating the safety and efficacy of GM-CSF (sargramostim) in Alzheimer's disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• sargramostim (sargramostim)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Alzheimer Disease | Phase 2 | Status: RECRUITING